These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 30965069)

  • 1. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.
    Srivastava A; Gailer R; Tanwar S; Trembling P; Parkes J; Rodger A; Suri D; Thorburn D; Sennett K; Morgan S; Tsochatzis EA; Rosenberg W
    J Hepatol; 2019 Aug; 71(2):371-378. PubMed ID: 30965069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
    Kjaergaard M; Lindvig KP; Thorhauge KH; Andersen P; Hansen JK; Kastrup N; Jensen JM; Hansen CD; Johansen S; Israelsen M; Torp N; Trelle MB; Shan S; Detlefsen S; Antonsen S; Andersen JE; Graupera I; Ginés P; Thiele M; Krag A
    J Hepatol; 2023 Aug; 79(2):277-286. PubMed ID: 37088311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease.
    Srivastava A; Jong S; Gola A; Gailer R; Morgan S; Sennett K; Tanwar S; Pizzo E; O'Beirne J; Tsochatzis E; Parkes J; Rosenberg W
    BMC Gastroenterol; 2019 Jul; 19(1):122. PubMed ID: 31296161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there scope to improve the selection of patients with alcohol-related liver disease for referral to secondary care? A retrospective analysis of primary care referrals to a UK liver centre, incorporating simple blood tests.
    Rhodes FA; Cococcia S; Patel P; Panovska-Griffiths J; Tanwar S; Westbrook RH; Rodger A; Rosenberg W
    BMJ Open; 2021 Jun; 11(6):e047786. PubMed ID: 34088709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
    Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
    J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simple blood fibrosis tests reduce unnecessary referrals for specialized evaluations of liver fibrosis in NAFLD and ALD patients.
    Broussier T; Lannes A; Zuberbuhler F; Oberti F; Fouchard I; Hunault G; Cales P; Boursier J
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):349-355. PubMed ID: 31422033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis.
    Crossan C; Majumdar A; Srivastava A; Thorburn D; Rosenberg W; Pinzani M; Longworth L; Tsochatzis EA
    Liver Int; 2019 Nov; 39(11):2052-2060. PubMed ID: 31332938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NAFLD: Diagnostic Algorithms for Regulating Patient Fluxes.
    Pallini G; Tsochatzis EA
    Curr Pharm Des; 2021; 27(27):3036-3046. PubMed ID: 33504297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
    Blond E; Disse E; Cuerq C; Drai J; Valette PJ; Laville M; Thivolet C; Simon C; Caussy C
    Diabetologia; 2017 Jul; 60(7):1218-1222. PubMed ID: 28352941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis.
    Boursier J; de Ledinghen V; Leroy V; Anty R; Francque S; Salmon D; Lannes A; Bertrais S; Oberti F; Fouchard-Hubert I; Calès P
    J Hepatol; 2017 Jun; 66(6):1158-1165. PubMed ID: 28088581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD.
    Ciardullo S; Ronchetti C; Muraca E; Oltolini A; Perra S; Bianconi E; Zerbini F; Cannistraci R; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    J Endocrinol Invest; 2020 Jul; 43(7):1019-1026. PubMed ID: 32008185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Only one-third of referrals for fatty liver disease are on time: real-world study reveals opportunities to avoid unnecessary and delayed referrals.
    Lindvig KP; Wernberg CW; Kjaergaard M; Thorhauge KH; Alnor AB; Thiele M; Krag A
    Scand J Gastroenterol; 2022 Dec; 57(12):1478-1485. PubMed ID: 35793386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
    Stål P
    World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population.
    Zambrano-Huailla R; Guedes L; Stefano JT; de Souza AAA; Marciano S; Yvamoto E; Michalczuk MT; Vanni DS; Rodriguez H; Carrilho FJ; Alvares-da-Silva MR; Gadano A; Arrese M; Miranda AL; Oliveira CP
    Ann Hepatol; 2020; 19(6):622-626. PubMed ID: 32919087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
    Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
    Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes.
    Gracen L; Hayward KL; Aikebuse M; Russell A; O'Beirne J; McPhail S; Irvine KM; Williams S; Valery PC; Powell EE
    BMC Health Serv Res; 2022 Apr; 22(1):487. PubMed ID: 35413987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
    Vilar-Gomez E; Chalasani N
    J Hepatol; 2018 Feb; 68(2):305-315. PubMed ID: 29154965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease.
    Cholankeril G; Kramer JR; Chu J; Yu X; Balakrishnan M; Li L; El-Serag HB; Kanwal F
    J Hepatol; 2023 Mar; 78(3):493-500. PubMed ID: 36402450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms.
    Lykiardopoulos B; Hagström H; Fredrikson M; Ignatova S; Stål P; Hultcrantz R; Ekstedt M; Kechagias S
    PLoS One; 2016; 11(12):e0167776. PubMed ID: 27936091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.